2025-05-22 16:54:00来源：浏览量：33
SERENA-6 研究的全体大会报告将聚焦用于晚期 HR 阳性乳腺癌一线治疗的新一代口服 SERD 药物 Camizestrant
MATTERHORN 研究的全体大会报告将展示英飞凡用于早期胃和胃食管结合部腺癌的围手术期治疗方案
DESTINY-Breast09 研究的专场口头报告将强调优赫得在 HER2 阳性转移性乳腺癌更前线治疗的潜力
上海 2025年5月22日 /美通社/ -- 阿斯利康在2025年5月30日至6月3日召开的美国临床肿瘤学会（ASCO）上，凭借行业领先的多样化产品与管线布局的全新研究数据，进一步深化自身让癌症不再成为致死主因的雄心。
会上将有超过80个摘要公布，其中涵盖20款已获得批准的药物和潜在新药，包括两项重磅研究的全体大会报告（plenary presentation），一项特别重磅研究摘要口头报告（late-breaking oral abstract session），以及19项口头报告。其中亮点包括：
阿斯利康全球执行副总裁、全球肿瘤研发负责人高书璨（ Susan Galbraith）表示："本次ASCO大会上公布的两项乳腺癌重磅研究数据将凸显我们在以创新药物和产品管线改变肿瘤治疗结局上所取得的进展。SERENA-6是首个采用循环肿瘤DNA检测指导治疗方案切换的一项关键III期临床研究，开创了这一技术在一线治疗中的应用，以延缓HR阳性、HER2阴性晚期乳腺癌的疾病进展。此外，DESTINY-Breast09研究评估了德曲妥珠单抗与帕妥珠单抗的联合治疗方案，这是十年来首次在HER2阳性转移性乳腺癌广泛患者群体中，证明疗效优于目前一线治疗标准方案的试验。"
阿斯利康全球执行副总裁，全球肿瘤研发负责人Dave Fredrickson表示："MATTERHORN的研究数据证明，度伐利尤单抗作为胃和胃食管结合部腺癌患者围手术期的治疗方案，是我们将免疫疗法迁入癌症早期阶段治疗的成功例证，有望实现早期治愈的可能。这是阿斯利康连续第七年登上ASCO全体大会，这一非凡的里程碑彰显出我们在多个癌肿领域已建立行业领先的肿瘤产品组合和强大的研发管线。
阿斯利康与第一三共联合开发和商业化德曲妥珠单抗与Datroway；与默沙东（默沙东是美国新泽西州罗威市默克公司的公司商号）联合开发和商业化司美替尼；与和黄医药合作开发和商业化赛沃替尼。
阿斯利康在 2025 年 ASCO 大会期间的重要演讲 1
| 主要作者 | 摘要标题 | 演示文稿详情 (CDT) |
| 抗体偶联药物 | ||
| Shitara, K
| Trastuzumab deruxtecan (T- DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study. | Abstract #LBA4002 Oral Abstract Session 31 May 2025 3:24pm
|
| Tolaney, SM
| Trastuzumab deruxtecan (T- DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | Abstract #LBA1008 Oral Abstract Session 2 June 2025 7:30am
|
| Dent, R
| Exploratory biomarker analysis of trastuzumab deruxtecan (T- DXd) vs physician's choice of chemotherapy (TPC) in HER2- low/-ultralow, hormone receptor-positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06). | Abstract #1013 Oral Abstract Session 31 May 2025 3:23pm
|
| Levy, BP
| TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first- line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). | Abstract #8501 Oral Abstract Session 1 June 2025 8:12am
|
| Waqar, SN
| First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). | Abstract #8521 Poster Session 31 May 2025 1:30pm
|
| 肿瘤驱动因素和耐药性 | ||
| Turner, NC
| Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial. | Abstract #LBA4 Plenary Session 1 June 2025 2:41pm
|
| Lu, S
| Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study. | Abstract #LBA8505 Oral Abstract Session 1 June 2025 9:48am
|
| Levy, BP
| Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO). | Abstract #8513 Rapid Oral Abstract Session 2 June 2025 8:06am
|
| Chaft JE
| Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA. | Abstract #8001 Oral Abstract Session 2 June 2025 3:12pm
|
| 免疫肿瘤学与双特异性抗体 | ||
| Janjigian, YY
| Event-free survival in MATTERHORN: a randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). | Abstract #LBA5 Plenary Session 1 June 2025 3:13pm
|
| Powles, T
| Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA | Abstract #4503 Oral Abstract Session 1 June 2025 10:45am
|
| Reck, M
| Associations of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial. | Abstract #8009 Rapid Oral Abstract Session 1 June 2025 4:30pm
|
| Barbie, DA
| Clinical and molecular characteristics of early progressors (EPs) and long -term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC). | Abstract #8014 Rapid Oral Abstract Session 1 June 2025 5:12pm
|
| Mayadev, J
| Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses. | Abstract #5502 Oral Abstract Session 2 June 2025 8:48am
|
| Westin, SN
| Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA. | Abstract #5512 Rapid Oral Abstract Session 3 June 2025 8:30am
|
| Erinjeri, JP
| Outcomes by baseline tumor burden using the 6-and-12 score in EMERALD-1: a phase 3 study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolization (TACE) in embolization-eligible unresectable hepatocellular carcinoma (uHCC). | Abstract #4083 Poster Session 31 May 2025 9:00am
|
| Cascone, T
| Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2. | Abstract #8046 Poster Session 31 May 2025 1:30pm
|
| Zhou, J
| First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): Primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A. | Abstract #4080 Poster Session 31 May 2025 9:00am
|
| Xu, R
| ARTEMIDE-Gastric01: a phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T- DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC). | Abstract #TPS4204 Poster Session 31 May 2025 9:00am
|
| Mathias, C
| ARTEMIDE-Lung03: a phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non- small-cell lung cancer whose tumors express PD-L1. | Abstract #TPS8653 Poster Session 31 May 2025 1:30pm
|
| 细胞疗法 | ||
| Yoo, C
| RHEA-1: First-in-human (FIH) study of AZD9793, a first-in- class CD8-guided T cell- engager (TCE) for glypican-3- positive (GPC3+) advanced or metastatic hepatocellular carcinoma (HCC). | Abstract #TPS4215 Poster Session 31 May 2025 9:00am
|
| Kim, TM
| Safety and Efficacy of AZD0486, a CD19xCD3 T-cell Engager, in Relapsed or Refractory Diffuse Large B-cell Lymphoma. | Abstract #7046 Poster Session 1 June 2025 9:00am
|
| Shadman, M
| TITANium: An open-label, global multicenter Phase 1/2 study of AZD5492, a first-in- class subcutaneous CD8- guided tri-specific T-cell engager (TCE), in patients (pts) with relapsed or refractory (r/r) B-cell malignancies. | Abstract #TPS7091 Poster Session 1 June 2025 9:00am
|
| Le Gouill, S
| SOUNDTRACK-E: A Phase 1/2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or Combination Therapy in Patients With Mature B-cell Malignancies. | Abstract #TPS7083 Poster Session 1 June 2025 9:00am
|
| 罕见病药物 | ||
| Chen, AP
| Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN): Primary analysis of KOMET (NCT04924608), a Phase 3, international, randomized, placebo-controlled study. | Abstract #3014 Rapid Oral Abstract Session 2 June 2025 8:00am
|
1 阿斯利康在2025年ASCO大会将公布超过80个摘要，涵盖其产品和管线中的分子药物
关于阿斯利康肿瘤领域的研究
阿斯利康正引领着肿瘤领域的一场革命，致力提供多元化的肿瘤治疗方案，以科学探索肿瘤领域的复杂性，发现、研发并向患者提供改变生命的药物。
阿斯利康专注于最具挑战性的肿瘤疾病，通过持续不断的创新，阿斯利康已经建立了行业领先的多元化的产品组合和管线，持续推动医疗实践变革，改变患者体验。
阿斯利康以期重新定义癌症治疗并在未来攻克癌症。
关于阿斯利康
阿斯利康（LSE/STO/Nasdaq: AZN）是一家科学至上的全球生物制药企业，专注于研发、生产及营销处方类药品，重点关注肿瘤、罕见病以及包括心血管肾脏及代谢、呼吸及免疫在内的生物制药等领域。阿斯利康全球总部位于英国剑桥，业务遍布超过125个国家，创新药物惠及全球数百万患者。
关于阿斯利康中国
阿斯利康自1993年进入中国以来，专注中国患者需求最迫切的治疗领域，包括肿瘤、心血管、肾脏、代谢、呼吸、消化、罕见病、疫苗抗体及自体免疫等，已将40多款创新药物带到中国。阿斯利康中国总部位于上海，并在上海和北京设立全球战略研发中心，在北京、广州、杭州、成都、青岛设立区域总部，在无锡、泰州、青岛建立全球生产供应基地，向全球70多个市场输送优质创新药品。
声明：本文研究中涉及的多种药品用法尚未在中国获批适应症，阿斯利康不推荐任何未被批准的药品使用。
微信公众号
药方舟手机版
